This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Common Sense for Drug Policy | |
|---|---|
| Name | Common Sense for Drug Policy |
| Formation | 1995 |
| Type | Nonprofit organization |
| Headquarters | United States |
| Leader title | Chairman |
| Leader name | Rick Lines |
Common Sense for Drug Policy is a United States-based advocacy organization focused on drug policy reform, harm reduction, and public health approaches to substance use. It engages with legislative bodies, think tanks, civil society groups, and international forums to promote alternatives to prohibitionist models and to reduce drug-related harms. The organization intersects with policy debates involving public health, criminal justice, and international drug control frameworks.
Common Sense for Drug Policy operates at the intersection of legislative advocacy, public health outreach, and policy research. It often participates in discussions alongside organizations such as the Brookings Institution, Cato Institute, RAND Corporation, Human Rights Watch, and Open Society Foundations, and it engages with policymakers from institutions like the United States Congress, European Commission, and United Nations Office on Drugs and Crime. The group advances proposals influenced by evidence produced by agencies and bodies including the Centers for Disease Control and Prevention, World Health Organization, Pan American Health Organization, Johns Hopkins University, and Harvard School of Public Health.
Founded in 1995, Common Sense for Drug Policy emerged amid debates shaped by events such as the War on Drugs, the Violent Crime Control and Law Enforcement Act of 1994, and international agreements like the Single Convention on Narcotic Drugs. Early supporters included figures associated with organizations like the Drug Policy Alliance, National Institute on Drug Abuse, and the American Civil Liberties Union. The group developed in parallel with policy shifts propelled by cases considered by the United States Supreme Court and legislative reforms in jurisdictions including Portugal, Uruguay, and various states such as Colorado and Washington (state).
Common Sense for Drug Policy advocates harm reduction measures such as syringe service programs promoted by the Centers for Disease Control and Prevention, supervised consumption sites examined in pilot studies by institutions like Addiction Research Foundation, and expanded access to opioid agonist therapies including medications endorsed by the Food and Drug Administration. It supports criminal justice reforms comparable to the reforms enacted in California Proposition 47, sentencing revisions influenced by the Fair Sentencing Act of 2010, and diversion programs modeled on initiatives in Portugal and Switzerland. On cannabis policy it engages with regulatory frameworks similar to those adopted in Canada and Massachusetts, and on psychedelic-assisted therapy it references clinical work at Johns Hopkins University and approvals discussed with the Drug Enforcement Administration and the Food and Drug Administration.
The organization has run campaigns targeting legislators in bodies such as the United States Senate, House of Representatives, and state legislatures, often coordinating with coalitions including Treatment Advocacy Center, Harm Reduction Coalition, National Governors Association, and Association of American Physicians and Surgeons. It has filed amicus briefs in cases before the United States Supreme Court and submitted testimony to committees chaired by members of the Senate Judiciary Committee and the House Committee on Energy and Commerce. Public outreach has included partnerships with media outlets like NPR, The New York Times, The Washington Post, and appearances at conferences hosted by South by Southwest, American Public Health Association, and International Harm Reduction Conference.
Scholars and advocates have credited Common Sense for Drug Policy with influencing debates on harm reduction and with contributing to policy shifts in jurisdictions including New York (state), California, Oregon, and several European states. Critics from organizations such as Mothers Against Drunk Driving, Drug Free America Foundation, and some factions within the Republican National Committee argue that its positions risk normalizing substance use; academic critiques have appeared in journals associated with Oxford University Press, Cambridge University Press, and research centers at Columbia University and University College London. Legal challenges and policy disputes have involved entities like the Department of Justice, Centers for Medicare & Medicaid Services, and state attorneys general.
The organization’s funding sources have included private foundations such as the Open Society Foundations, philanthropic organizations connected to figures referenced in coverage by The Guardian, as well as donations routed through intermediaries similar to those used by the Rockefeller Foundation and private donors tied to policy networks like Results for Development. Its board and advisory panels have included individuals with affiliations to institutions such as Harvard University, Yale University, Georgetown University, Columbia University, Johns Hopkins University, and former policymakers from administrations including the Clinton administration and Obama administration.
Internationally, Common Sense for Drug Policy has engaged with multilateral processes at the United Nations General Assembly, Commission on Narcotic Drugs, and regional bodies such as the European Parliament and the Organization of American States. It has participated in dialogues alongside delegations from countries including Portugal, Uruguay, Canada, Mexico, Switzerland, and Australia, and it has worked with international NGOs like Médecins Sans Frontières, International Drug Policy Consortium, and Amnesty International to promote alternatives to punitive approaches reflected in treaties like the 1961 Single Convention on Narcotic Drugs and discussions tied to the 2030 Agenda for Sustainable Development.
Category:Drug policy organizations